MARKET

JBIO

JBIO

Jade Biosciences Inc
NASDAQ
17.89
-0.34
-1.87%
After Hours: 17.70 -0.19 -1.06% 17:25 04/10 EDT
OPEN
18.32
PREV CLOSE
18.23
HIGH
18.49
LOW
17.37
VOLUME
654.49K
TURNOVER
--
52 WEEK HIGH
18.49
52 WEEK LOW
1.121
MARKET CAP
882.27M
P/E (TTM)
-5.6027
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JBIO last week (0330-0403)?
Weekly Report · 6d ago
Jade Biosciences (JBIO) Receives a Rating Update from a Top Analyst
TipRanks · 6d ago
Jade Biosciences Adopts 2026 Employment Inducement Stock Plan
TipRanks · 04/02 20:42
Jade Biosciences launches inducement equity plan, reserves 1.75 million shares
Reuters · 04/02 20:12
Weekly Report: what happened at JBIO last week (0323-0327)?
Weekly Report · 03/30 10:41
Jade Biosciences Price Target Raised to $35.00/Share From $25.00 by HC Wainwright & Co.
Dow Jones · 03/25 11:06
Jade Biosciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/25 11:06
HC Wainwright & Co. Maintains Buy on Jade Biosciences, Raises Price Target to $35
Benzinga · 03/25 10:57
More
About JBIO
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.

Webull offers Jade Biosciences Inc stock information, including NASDAQ: JBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JBIO stock methods without spending real money on the virtual paper trading platform.